Smythies, J.R. (1960). New research frontiers in parapsychology and pharmacology. International Journal of Parapsychology, 2/2, 28-38.

Of those reporting the use of psychedelics, between 18% and 83% reported ESP experiences – most commonly telepathy but also precognition – actually occurring during drug use, with heavier users reporting more experiences where specified. Yet, conversely, the occurrence of psychokinesis during drug use was only reported to occur by between 13% and 22% of those using psychedelics. 26 Miyamoto, S.; Duncan, G.E.; Marx, C.E.; Lieberman, J.A. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10, 79–104. Psychedelic" redirects here. For other uses, see Psychedelic (disambiguation). Synthetic mescaline. Normally biosynthesized from peyote and some other cacti, mescaline was the first psychedelic compound to be extracted and isolated. [1] British Association for Psychopharmacology of Schizophrenia. Evidence-Based Guidelines for the Pharmacological Treatment of Schizophrenia: Recommendations from the British Association for Psychopharmacology. Available online: https://www.bap.org.uk (accessed on 7 November 2021). Thompson, C.; Szabo, A. Psychedelics as a novel approach to treating autoimmune conditions. Immunol. Lett. 2020, 228, 45–54.Hayashi, T.; Ko, J.H.; Strafella, A.P.; Dagher, A. Dorsolateral prefrontal and orbitofrontal cortex interactions during self-control of cigarette craving. Proc. Natl. Acad. Sci. USA 2013, 110, 4422–4427. Tart, C.T. (1968). Hypnosis, psychedelics, and psi: Conceptual models. In Psi and Altered States of Consciousness: Proceedings of an International Conference on Hypnosis, Drugs, Dreams, and Psi, ed. by R. Cavanna & M. Ullman, 24-41. New York: Parapsychology Foundation.

Palmer, J. (1979). A community mail survey of psychic experiences. Journal of the American Society for Psychical Research 73, 221-51.Nichols, D.E.; Johnson, M.W.; Nichols, C.D. Psychedelics as Medicines: An Emerging New Paradigm. Clin. Pharmacol. Ther. 2017, 101, 209–219. Newcomer, J.W.; Hennekens, C.H. Severe mental illness and risk of cardiovascular disease. JAMA 2007, 298, 1794–1796. Cardeña, E. & Pekala, R. (2014). Researching states of consciousness and anomalous experiences. In Varieties of anomalous experience (2nd ed.) ed. by E. Cardeña, S.J. Lynn & S. Krippner, 21-56. Washington, DC: American Psychological Association. Slocum, S.T.; DiBerto, J.F.; Roth, B.L. Molecular insights into psychedelic drug action. J. Neurochem. 2021. Bunzow, J.R.; Sonders, M.S.; Arttamangkul, S.; Harrison, L.M.; Zhang, G.; Quigley, D.I.; Darland, T.; Suchland, K.L.; Pasumamula, S.; Kennedy, J.L.; et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 2001, 60, 1181–1188.

Hennekens, C.H.; Hennekens, A.R.; Hollar, D.; Casey, D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 2005, 150, 1115–1121.

Navigation menu

Strassman, R.J., Qualls, C.R., Uhlenhuth, E.H., & Kellner, R. (1994). Dose-response study of N,N-dimethyltryptamine in humans: II Subjective effects and preliminary results of a new rating scale. Archives of General Psychiatry 51, 98-108. Auquier, P.; Lançon, C.; Rouillon, F.; Lader, M.; Holmes, C. Mortality in schizophrenia. Pharmacoepidemiol. Drug Saf. 2006, 15, 873–879.

Crystal Structure of LSD and 5-HT2AR Part 2: Binding Details and Future Psychedelic Research Paths". Psychedelic Science Review. 2020-10-05 . Retrieved 2021-02-12.García-Gutiérrez, M.S.; Navarrete, F.; Sala, F.; Gasparyan, A.; Austrich-Olivares, A.; Manzanares, J. Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality. Front. Psychiatry 2020, 11, 432. Nilsson, I.A.K.; Millischer, V.; Karrenbauer, V.D.; Juréus, A.; Salehi, A.M.; Norring, C.; von Hausswolff-Juhlin, Y.; Schalling, M.; Blennow, K.; Bulik, C.M.; et al. Plasma neurofilament light chain concentration is increased in anorexia nervosa. Transl. Psychiatry 2019, 9, 180. Tart 86 has further suggested that marijuana is an ideal substance for psi experimentation because of its wide familiarity, its mild psychedelic qualities, and its reputed ability to induce psi, experientially at least. Puharich’s 87 apparent repeated success with Amanita muscaria also needs replicating. Other, non-psychedelic chemical psi research, such as Pablos’s 88 unsuccessful first-person precognitive-dream drug-study, could also be replicated with the use of psychedelic substances that have been reported to induce psi in dreams, such as the ostensibly precognitive dreams described by both traditional users and by modern consciousness researchers in relation to substances such as C alea zacatechichi, 89 Silene capensis, 90 and tree datura ( Brugmansia). 91 While the method of action of psychedelics is not fully understood, they are known to show affinities for various 5-HT (serotonin) receptors in different ways and levels, and may be classified by their activity at different 5-HT sub-types, particularly 5-HT 1A, 5-HT 2A, and 5-HT 2C. [32] It is almost unanimously agreed that psychedelics produce their effect by acting as strong partial agonists at the 5-HT 2A receptors. [2] [73] [9] [10] How this produces the psychedelic experience is unclear, but it is likely that it acts by increasing excitation in the cortex, possibly by specifically facilitating input from the thalamus, the major relay for sensory information input to the cortex. [32] [74] Additionally, researchers discovered that many psychedelics are potent psychoplastogens, compounds capable of promoting rapid and sustained neural plasticity. [75] [76] Tryptamines [ edit ] N,N-DMT